Early state molecular diagnostic start-up required go to market plan to secure early stage angel funding.
Development of business plan focused generating clinical trial revenue to support ongoing clinical validation of technology. Leveraging key opinion leader support in the form of testimonials to demonstrate market potential and patient benefit of novel assay for the early detection of breast cancer chemotherapy effectiveness.
Supported syndicated investor raise. Provided firm with resources to continue commercialization process.